ORIC Pharmaceuticals (FRA:4TZ) ROCE %: -39.49% (As of Mar. 2026)


FRA:4TZ ORIC Pharmaceuticals Inc FRA:4TZ
32 GF Score
Price €9.13
! 3 Warning Signs
View Full Analysis

What is ORIC Pharmaceuticals ROCE %?

ORIC Pharmaceuticals FRA:4TZ -2.77% 32 ROCE % is -39.49% as of Mar. 2026. GuruFocus rates FRA:4TZ with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ORIC Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was -39.49%.

ORIC Pharmaceuticals  (FRA:4TZ) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ORIC Pharmaceuticals ROCE % Related Terms

ORIC Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for ORIC Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ORIC Pharmaceuticals ROCE % Chart

ORIC Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -28.53 -34.88 -47.12 -60.60 -42.86

ORIC Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.23 -54.91 -39.35 -34.62 -39.49
FRA:4TZ
32GF Score
ORIC Pharmaceuticals Inc FRA:4TZ
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ORIC Pharmaceuticals ROCE % Calculation

ORIC Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-122.125/( ( (261.806 - 23.728) + (349.192 - 17.436) )/ 2 )
=-122.125/( (238.078+331.756)/ 2 )
=-122.125/284.917
=-42.86 %

ORIC Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-137.08/( ( (349.192 - 17.436) + (377.799 - 15.372) )/ 2 )
=-137.08/( ( 331.756 + 362.427 )/ 2 )
=-137.08/347.0915
=-39.49 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -39.49% mean?
ORIC Pharmaceuticals (FRA:4TZ) has a ROCE % of -39.49% as of Mar. 2026.
Is ORIC Pharmaceuticals' ROCE % too high?
ORIC Pharmaceuticals' current ROCE % is -39.49%. Overall, ORIC Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does ORIC Pharmaceuticals' ROCE % compare to DRTS and OLMA?
ORIC Pharmaceuticals' ROCE % of -39.49% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. ORIC Pharmaceuticals's current ROCE % is -39.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ORIC Pharmaceuticals stock overvalued right now?
ORIC Pharmaceuticals (FRA:4TZ) has a current ROCE % of -39.49%. The current ROCE % is -39.49%. ORIC Pharmaceuticals' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For ORIC Pharmaceuticals (FRA:4TZ), the current ROCE % is -39.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ORIC Pharmaceuticals Business Description

Other Exchanges ORIC:USA
Address 240 E. Grand Avenue, 2nd Floor, South San Francisco, CA, USA, 94080
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
32GF Score

Get the complete analysis for FRA:4TZ

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.13
Price